- Reaction score
- 96
On the 14th, Hanmo Bio (CEO Yoon Jung-in), an affiliate of Han Bio Group, a cell-specialized bio company, signed a 'clinical comprehensive service contract' with a clinical-related institution Dt&CRO (CEO Park Chae-gyu) on the 14th. It was announced on the 19th that it would start clinical trials. The service contract also includes clinical trials on the development of NK cell therapy products, stem cell therapy products, and dermal papilla cell cultures, including dermal papilla cells. DTNCRO is a specialized institution with extensive clinical experience, including non-clinical efficacy and toxicity tests, and clinical trials, based on its experience in conducting clinical trials of various new drugs and cell therapy products. Hanmo Bio and DTNCRO agreed to start a non-clinical trial in November with respect to the development of a dermal papilla cell therapy, and are pursuing clinical trials with the goal of applying for an IND for phase 1 clinical trial in the first half of next year. It plans to complete clinical trials and product approval as soon as possible. In addition, it said that it plans to continuously conduct related non-clinical tests for registration of NK cell therapy and stem cell therapy, which are the main fields of Han Bio Group, and the registration of cosmetic raw materials using cell culture medium. Hanbio Group established Hanmo Bio, which specializes in dermal papilla cell research, in April 2020 after successful mass culture of dermal papilla cells, which act like the seeds of hair, based on the accumulated stem cell and NK immune cell culture technology. did. After that, Hanmo Bio Co., Ltd. started full-scale R&D on dermal papilla cell isolation-culture-transplantation for hair loss treatment, and officially announced the success of mass culture of dermal papilla cells in September 2020. Subsequently, in the first half of 2021, patents were registered for the ‘Isolation and Mass Proliferation Method of Scalp Tissue-derived dermal papilla cells’ and ‘The method of transplanting dermal papilla cells through perforation’, which are the basic technologies for hair loss treatment. “Through this clinical contract, the development of dermal papilla cell culture transplantation and treatment, which can be an innovative alternative to hair loss treatment, has started in earnest,” said David Kang, chairman of Hanbio Group. By starting non-clinical studies on cell culture as well as clinical trials in Korea, we have started a long journey for the development of various related products along with the development of cell therapy products.” Jung Hee-young, reporter for Money Today Broadcast MTN
한모바이오, 탈모치료 위한 모유두세포 이식 임상 절차 돌입 - 머니투데이방송 (mtn.co.kr)
한모바이오, 탈모치료 위한 모유두세포 이식 임상 절차 돌입 - 머니투데이방송 (mtn.co.kr)